Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Dermatologic 1

Conditions

Melanoma 2Uveal Melanoma 1Ovarian Neoplasms 1

Interventions

Ipilimumab 29Nivolumab 23pembrolizumab 14incomplete Freund's adjuvant 10Cyclophosphamide 10Melphalan 9Interleukin-2 9CTLA-4 Antigen 8tebentafusp 7sargramostim 7Temozolomide 7MART-1 Antigen 7Dacarbazine 7Ranibizumab 6montanide ISA 51 5fludarabine phosphate 5fludarabine 5Sunitinib 5Radiosurgery 5Carboplatin 5Blood Specimen Collection 5Bevacizumab 5aldesleukin 4aflibercept 4Surveys and Questionnaires 4Magnetic Resonance Spectroscopy 4Granulocyte-Macrophage Colony-Stimulating Factor 4Biopsy 4trametinib 3sotrastaurin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × Polyethylene Glycols × Dermatologic × Clear all
NCT01665183 2016-02-25

Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

Polaris Group

Phase 1 Completed
8 enrolled
DermatologicGynecologic

Uveal Melanoma, Melanoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡